A. Schacht

发表

Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.

M. Lambert, D. Naber, B. Schimmelmann, 2006, The Journal of clinical psychiatry.

Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life.

R. Barkley, P. Wehmeier, A. Schacht, 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Multilevel network meta‐regression for population‐adjusted treatment comparisons

David M. Phillippo, N. Welton, A. Ades, 2020, Journal of the Royal Statistical Society. Series A,.

Combination of several matching adjusted indirect comparisons (MAICs) with an application in psoriasis

Alexander Schacht, Daniel Saure, Zbigniew Kadziola, 2020, Pharmaceutical statistics.

Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study

G. Cruccu, D. Bouhassira, E. Kosek, 2014, PAIN®.

Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain

G. Cruccu, D. Bouhassira, S. Tesfaye, 2013, PAIN®.

Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom

M. Happich, A. Schacht, N. Shi, 2012, Journal of medical economics.

Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.

M. Berk, S. Dodd, A. Schacht, 2013, Journal of affective disorders.

Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever

T. Pollmächer, R. Dittmann, T. Kraus, 2009, Psychoneuroendocrinology.

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD

S. Ruberg, O. Keene, D. Wright, 2020, Pharmaceutical statistics.

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

R. Burge, C. Leonardi, B. Zhu, 2017, Journal of medical economics.

Rates and predictors of remission and recovery during 3 years in 392 never‐treated patients with schizophrenia

M. Lambert, D. Naber, H. Hundemer, 2008, Acta psychiatrica Scandinavica.

Letter to the Editor in Response to recently published article, ‘Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis’

A. Gottlieb, K. Papp, S. Ball, 2017 .

Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trials.

P. Gorwood, P. Boyce, A. Schacht, 2014, Journal of psychiatric research.

Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.

M. Lambert, D. Naber, R. Dittmann, 2007, The Journal of clinical psychiatry.

Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients

M. Lambert, D. Naber, H. Hundemer, 2008, Schizophrenia Research.

Atomoxetine's Effect on Societal Costs in Sweden

P. Svanborg, A. Schacht, K. Myren, 2010, Journal of attention disorders.

Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD-related difficulties, and patients’ emotional expression during psychostimulant or nonstimulant ADHD treatment

T. Banaschewski, R. Dittmann, P. Wehmeier, 2014, ADHD Attention Deficit and Hyperactivity Disorders.

Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials.

M. Berk, L. Williams, G. Malhi, 2015, The Journal of clinical psychiatry.

Depression Treatment with Duloxetine and Reduction of Inability to Work

M. Happich, A. Schacht, E. Schneider, 2012, Depression research and treatment.

Long-term patterns of subjective wellbeing in schizophrenia: Cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years

M. Lambert, D. Naber, R. Dittmann, 2008, Schizophrenia Research.

Web-based Supplementary Materials for ” A new non-parametric approach for baseline covariate adjustment for two-group comparative studies

E. Lesaffre, K. Bogaerts, E. Bluhmki, 2008 .

Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches

M. Boeri, A. Schacht, B. Hauber, 2020, PharmacoEconomics.

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

J. Buitelaar, P. Hoekstra, R. Minderaa, 2012, Journal of the American Academy of Child and Adolescent Psychiatry.

Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab

R. Warren, K. See, A. Nast, 2018, The British journal of dermatology.

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

A. Gottlieb, J. Erickson, A. Schacht, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

K. Reich, M. Augustin, U. Mrowietz, 2019, The British journal of dermatology.

Antidepressants in the Treatment for Chronic Low Back Pain: Questioning the Validity of Meta‐Analyses

O. Williamson, A. Schacht, R. Bruins, 2014, Pain practice : the official journal of World Institute of Pain.

Olanzapine and clozapine differently affect sleep in patients with schizophrenia: Results from a double-blind, polysomnographic study and review of the literature

T. Pollmächer, R. Dittmann, T. Kraus, 2014, Schizophrenia Research.

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses

A. Schacht, E. Anand, M. Casillas, 2013, Neuropsychiatric disease and treatment.

Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials

P. Wehmeier, A. Schacht, T. Wagner, 2011, Attention deficit and hyperactivity disorders.

Quality of Life and Attention-Deficit/Hyperactivity Disorder Core Symptoms: A Pooled Analysis of 5 Non-US Atomoxetine Clinical Trials

P. Wehmeier, A. Schacht, T. Wagner, 2010, Journal of clinical psychopharmacology.

Clozapine and Olanzapine Are Associated With Food Craving and Binge Eating: Results From A Randomized Double-Blind Study

T. Pollmächer, R. Dittmann, T. Kraus, 2007, Journal of clinical psychopharmacology.

Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain: Results from a German Observational Study

M. Happich, D. Ziegler, F. Birklein, 2014, The Clinical journal of pain.

Patient expectations in the treatment of painful diabetic polyneuropathy: results from a non-interventional study.

D. Ziegler, F. Birklein, A. Schacht, 2014, Pain medicine.

Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents

P. Svanborg, B. Kadesjö, P. Gustafsson, 2009, European Child & Adolescent Psychiatry.

Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.

M. Lambert, P. Wehmeier, B. Schimmelmann, 2008, Journal of psychiatric research.

Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia

P. Wehmeier, A. Schacht, M. Kluge, 2007, Schizophrenia Research.

Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.

M. Lambert, D. Naber, H. Hundemer, 2008, Pharmacopsychiatry.

BMC Psychiatry BioMed Central Research article Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: Results of an observational trial

A. Schacht, T. Wagner, S. Wilhelm, 2008 .

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

M. Bullinger, R. Dittmann, P. Wehmeier, 2011, Quality of Life Research.

Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.

G. Perugi, A. Schacht, M. Mancini, 2014, Journal of psychiatric research.

A New Nonparametric Approach for Baseline Covariate Adjustment for Two‐Group Comparative Studies

E. Lesaffre, K. Bogaerts, E. Bluhmki, 2008, Biometrics.

Structured Benefit–risk assessment: a review of key publications and initiatives on frameworks and methodologies

Shahrul Mt-Isa, Alexander Schacht, Mario Ouwens, 2016, Pharmaceutical statistics.

Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)

R. Dittmann, J. March, P. Wehmeier, 2008 .

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

G. Lehmkuhl, R. Dittmann, P. Wehmeier, 2011, Journal of child and adolescent psychopharmacology.

A. Hervás, P. Wehmeier, A. Schacht, 2012, ADHD Attention Deficit and Hyperactivity Disorders.

Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

V. Harpin, P. Wehmeier, A. Schacht, 2010, Child and adolescent psychiatry and mental health.

Does Comorbid Disruptive Behavior Modify the Effects of Atomoxetine on ADHD Symptoms as Measured by a Continuous Performance Test and a Motion Tracking Device?

T. Banaschewski, R. Dittmann, P. Wehmeier, 2015, Journal of attention disorders.

Does Stimulant Pretreatment Modify Atomoxetine Effects on Core Symptoms of ADHD in Children Assessed by Quantitative Measurement Technology?

T. Banaschewski, R. Dittmann, P. Wehmeier, 2014, Journal of attention disorders.

Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder

T. Banaschewski, R. Dittmann, P. Wehmeier, 2010, Attention deficit and hyperactivity disorders.

Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies.

G. Lehmkuhl, R. Dittmann, P. Wehmeier, 2009, Child and adolescent psychiatry and mental health.

Evaluation of Patient- and Parent-Rated Emotional Expression Using theExpression and Emotion Scale for Children (EESC) in an ObservationalStudy of ADHD in Children and Adolescents

P. Wehmeier, M. Huss, A. Schacht, 2012 .

Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.

V. Pérez, J. Menchón, A. Schacht, 2012, Journal of affective disorders.

Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings

G. Lehmkuhl, R. Dittmann, P. Wehmeier, 2009, Attention deficit and hyperactivity disorders.

Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients

B. Kinon, A. Schacht, T. Wagner, 2007, Patient preference and adherence.

Differential 3-Year Effects of First- Versus Second-Generation Antipsychotics on Subjective Well-Being in Schizophrenia Using Marginal Structural Models

J. Haro, M. Lambert, D. Naber, 2011, Journal of clinical psychopharmacology.

Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years

A. Rothenberger, P. Wehmeier, A. Schacht, 2009 .

Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians

G. Lehmkuhl, R. Dittmann, P. Wehmeier, 2009, Child and Adolescent Psychiatry and Mental Health.

Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.

G. Lehmkuhl, R. Dittmann, P. Wehmeier, 2007, Journal of child and adolescent psychopharmacology.

Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology

T. Banaschewski, G. Lehmkuhl, R. Dittmann, 2012, Journal of clinical psychopharmacology.

Early Switch Strategy in Patients With Major Depressive Disorder: A Double-Blind, Randomized Study

P. Svanborg, V. Pérez, J. Menchón, 2012, Journal of clinical psychopharmacology.

Different levels of lack of improvement at 4 weeks of escitalopram treatment as predictors of poor 8-week outcome in MDD.

J. Menchón, A. Schacht, V. Pérez-Solà, 2013, Journal of Affective Disorders.

Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia

P. Wehmeier, A. Schacht, T. Wagner, 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Does Early Improvement in Anxiety Symptoms in Patients with Major Depressive Disorder Affect Remission Rates? A Post-Hoc Analysis of Pooled Duloxetine Clinic Trials

A. Schacht, L. Berggren, D. Walker, 2014 .

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan

L. Marangell, A. Schacht, T. Koyama, 2015, Neuropsychiatric disease and treatment.

Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device.

T. Banaschewski, R. Dittmann, P. Wehmeier, 2011, Journal of child and adolescent psychopharmacology.

Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: Reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day

Alexander Schacht, R. Dittmann, P. Wehmeier, 2008, Child and adolescent psychiatry and mental health.

The assessment of non‐inferiority in a gold standard design with censored, exponentially distributed endpoints

Matthias Mielke, A. Munk, A. Schacht, 2008, Statistics in medicine.

A statistical method to convert published response rates into marginal distributions with an example application in psoriasis

U. Mrowietz, A. Schacht, H. Petto, 2018, Pharmaceutical statistics.

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses

A. Schacht, E. Anand, M. Casillas, 2013, Neuropsychiatric disease and treatment.

Child and Adolescent Psychiatry and Mental Health Change in the Direct Cost of Treatment for Children and Adolescents with Hyperkinetic Disorder in Germany over a Period of Four Years

A. Rothenberger, P. Wehmeier, A. Schacht, 2022 .

Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?

R. Mergl, U. Hegerl, M. Linden, 2012, Expert opinion on drug safety.

Critical evaluation of mixed treatment comparison meta‐analyses using examples assessing antidepressants and opioid detoxification treatments

A. Schacht, R. Walton, Y. Dyachkova, 2013, International journal of methods in psychiatric research.

T. Banaschewski, R. Dittmann, P. Wehmeier, 2011, Journal of child and adolescent psychopharmacology.

Child and Adolescent Psychiatry and Mental Health Morning and Evening Behavior in Children and Adolescents Treated with Atomoxetine Once Daily for Attention-deficit/hyperactivity Disorder (adhd): Findings from Two 24-week, Open-label Studies

G. Lehmkuhl, R. Dittmann, P. Wehmeier, 2022 .

Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom

M. Happich, A. Schacht, N. Shi, 2012, Journal of medical economics.